Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BRIDGEBIO PHARMA, INC.

(BBIO)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/22/2021 09/23/2021 09/24/2021 09/27/2021 09/28/2021 Date
49.94(c) 49.9(c) 48.57(c) 50.44(c) 50.1 Last
675 406 2 348 956 861 425 601 630 857 232 Volume
-0.48% -0.08% -2.67% +3.85% -0.67% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 110 M - -
Net income 2021 -520 M - -
Net Debt 2021 177 M - -
P/E ratio 2021 -13,8x
Yield 2021 -
Sales 2022 132 M - -
Net income 2022 -528 M - -
Net Debt 2022 646 M - -
P/E ratio 2022 -14,0x
Yield 2022 -
Capitalization 7 503 M 7 503 M -
EV / Sales 2021 69,5x
EV / Sales 2022 61,5x
Nbr of Employees 391
Free-Float 65,2%
More Financials
Company
BridgeBio Pharma, Inc. is a United States-based company, The Company discovers and develops medicines that target well-characterized genetic diseases. The Company’s product platform divided into three key categories: Mendelian, Oncology and Gene therapy. The Company’s pipeline programs include product candidates ranging from early discovery to late-stage development. The Company’s products include BBP-561,... 
Sector
Pharmaceuticals
Calendar
10/04 | 04:30pmPresentation
More about the company
Ratings of BridgeBio Pharma, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about BRIDGEBIO PHARMA, INC.
09/20BRIDGEBIO PHARMA : Corporate Presentation September 2021
PU
09/15BRIDGEBIO PHARMA : Gets Fast Track Designation From FDA for Muscular Dystrophy Drug Candid..
MT
09/15BRIDGEBIO : Pharma Receives FDA Fast Track Designation for Investigational Therapy for the..
PR
09/15BridgeBio Pharma Receives FDA Fast Track Designation for Investigational Therapy for th..
CI
09/15BridgeBio Gets FDA Fast-Track Designation for Limb-Girdle Muscular Dystrophy Type 2i Tr..
DJ
09/13BRIDGEBIO PHARMA : Corporate Presentation September 2021
PU
09/13NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
09/10BRIDGEBIO PHARMA : BofA Securities Upgrades BridgeBio Pharma to Buy From Neutral, Sets $75..
MT
09/09BRIDGEBIO PHARMA : Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
09/09BRIDGEBIO PHARMA : Corporate Presentation September 2021
PU
09/08BRIDGEBIO : Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR
08/25SECTOR UPDATE : Health Care Stocks Mixed Pre-Bell Wednesday
MT
08/25BRIDGEBIO PHARMA : LianBio Treat First Patient in Trial of Infigratinib for Gastric Cancer..
MT
08/25BRIDGEBIO PHARMA : and LianBio Announce First Patient Treated in Phase 2a Trial of Infigra..
BU
08/25LianBio and BridgeBio Pharma, Inc. Announce First Patient Treated in Phase 2a Trial of ..
CI
More news
News in other languages on BRIDGEBIO PHARMA, INC.

- No features available -

More news
Analyst Recommendations on BRIDGEBIO PHARMA, INC.
More recommendations
Chart BRIDGEBIO PHARMA, INC.
Duration : Period :
BridgeBio Pharma, Inc. Technical Analysis Chart | BBIO | US10806X1028 | MarketScreener
Technical analysis trends BRIDGEBIO PHARMA, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 50,10 $
Average target price 79,67 $
Spread / Average Target 59,0%
EPS Revisions
Managers and Directors
Neil Kumar Chief Executive Officer & Director
Brian C. Stephenson Chief Financial Officer & Secretary
Uma Sinha Chief Scientific Officer
Richard H. Scheller Director, Chairman-Research & Development
Christine E. Siu Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
BRIDGEBIO PHARMA, INC.-29.07%7 554
JOHNSON & JOHNSON3.45%429 542
ROCHE HOLDING AG9.24%319 352
PFIZER, INC.18.36%244 283
NOVO NORDISK A/S48.08%227 557
ELI LILLY AND COMPANY31.25%205 250